roadtoabilly的个人主页 - 老虎社区

roadtoabilly

roadtoabilly

newbie investor

IP属地：未知

3关注

1粉丝

0主题

0勋章

2021-05-04

$5 I will triple down

@MrRyo:$AMC院线(AMC)$估计要掉回5块了

2021-04-29

$AMC Entertainment(AMC)$Drop to $9 time to double down...

2021-04-26

$AMC Entertainment(AMC)$Moooooon!!

2021-04-23

$AMC Entertainment(AMC)$Come on baby, rise!

2021-04-20

buy more future is definitely bright

抱歉，原内容已删除

2021-04-16

pattern more than badminton at first say bad stock now say good stock

抱歉，原内容已删除

2021-04-02

$Paysafe Ltd(PSFE)$Rise

2021-03-30

$Foley Trasimene Acquisition II Corp(BFT)$[贱笑]

2021-03-27

$AMC Entertainment(AMC)$Buying more...

2021-03-24

$Foley Trasimene Acquisition II Corp(BFT)$🚀🚀🚀

2021-03-24

I am going to buy more!

抱歉，原内容已删除

2021-03-19

$Plug Power(PLUG)$next week fly?

2021-03-18

do opposite of motley fool = profit

3 Biotech Stocks to Avoid Right Now<blockquote>现在要避免的 3 只生物技术股票</blockquote>

2021-03-17

$AMC Entertainment(AMC)$🚀🚀🚀

2021-03-17

price target $200

抱歉，原内容已删除

2021-03-16

$Surface Oncology(SURF)$Hold...

2021-03-12

$AMC Entertainment(AMC)$ paper hand last time but not this time

2021-03-12

$Histogenics(OCGN)$ let's go! back to $18

2021-02-11

$Histogenics(OCGN)$Happy Chinese New Year 💎🖐

2021-02-10

$Histogenics(OCGN)$ lets go $20

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3573195863338760","uuid":"3573195863338760","gmtCreate":1610102413672,"gmtModify":1611800011716,"name":"roadtoabilly","pinyin":"roadtoabilly","introduction":"","introductionEn":null,"signature":"newbie investor","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":3,"tweetSize":24,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.07.02","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.98%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.45%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":106807303,"gmtCreate":1620098580802,"gmtModify":1634207823176,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573195863338760","idStr":"3573195863338760"},"themes":[],"title":"","htmlText":"$5 I will triple down","listText":"$5 I will triple down","text":"$5 I will triple down","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/106807303","repostId":"106197333","repostType":1,"repost":{"id":106197333,"gmtCreate":1620091938422,"gmtModify":1634207892994,"author":{"id":"3570747842137562","authorId":"3570747842137562","name":"MrRyo","avatar":"https://static.tigerbbs.com/104b6be5582f3acbc952a28eb3b52b8f","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570747842137562","idStr":"3570747842137562"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC院线(AMC)$</a>估计要掉回5块了","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC院线(AMC)$</a>估计要掉回5块了","text":"$AMC院线(AMC)$估计要掉回5块了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/106197333","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1590,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":100499694,"gmtCreate":1619626119018,"gmtModify":1634211211506,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573195863338760","idStr":"3573195863338760"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Drop to $9 time to&nbsp;double down...","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Drop to $9 time to&nbsp;double down...","text":"$AMC Entertainment(AMC)$Drop to $9 time to double down...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/100499694","isVote":1,"tweetType":1,"viewCount":3088,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":374663060,"gmtCreate":1619444663250,"gmtModify":1634273426576,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573195863338760","idStr":"3573195863338760"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Moooooon!!","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Moooooon!!","text":"$AMC Entertainment(AMC)$Moooooon!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/374663060","isVote":1,"tweetType":1,"viewCount":1800,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":372986368,"gmtCreate":1619168314754,"gmtModify":1634288039967,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573195863338760","idStr":"3573195863338760"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Come on baby, rise!","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Come on baby, rise!","text":"$AMC Entertainment(AMC)$Come on baby, rise!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/372986368","isVote":1,"tweetType":1,"viewCount":1990,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":371161941,"gmtCreate":1618921258083,"gmtModify":1634289905494,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573195863338760","idStr":"3573195863338760"},"themes":[],"title":"","htmlText":"buy more future is definitely bright&nbsp;","listText":"buy more future is definitely bright&nbsp;","text":"buy more future is definitely bright","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/371161941","repostId":"1111837627","repostType":2,"isVote":1,"tweetType":1,"viewCount":2399,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":370074800,"gmtCreate":1618539539900,"gmtModify":1634292217879,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573195863338760","idStr":"3573195863338760"},"themes":[],"title":"","htmlText":"pattern more than badminton at first say bad stock now say good stock","listText":"pattern more than badminton at first say bad stock now say good stock","text":"pattern more than badminton at first say bad stock now say good stock","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/370074800","repostId":"2127012213","repostType":2,"isVote":1,"tweetType":1,"viewCount":2043,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":357769122,"gmtCreate":1617302142866,"gmtModify":1631886377613,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573195863338760","idStr":"3573195863338760"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/PSFE\">$Paysafe Ltd(PSFE)$</a>Rise","listText":"<a href=\"https://laohu8.com/S/PSFE\">$Paysafe Ltd(PSFE)$</a>Rise","text":"$Paysafe Ltd(PSFE)$Rise","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/357769122","isVote":1,"tweetType":1,"viewCount":2080,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":355153979,"gmtCreate":1617041728691,"gmtModify":1631886377700,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573195863338760","idStr":"3573195863338760"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/BFT\">$Foley Trasimene Acquisition II Corp(BFT)$</a>[贱笑]&nbsp;","listText":"<a href=\"https://laohu8.com/S/BFT\">$Foley Trasimene Acquisition II Corp(BFT)$</a>[贱笑]&nbsp;","text":"$Foley Trasimene Acquisition II Corp(BFT)$[贱笑]","images":[{"img":"https://static.tigerbbs.com/4d103a9d850a22d203508f25c16a1c73","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/355153979","isVote":1,"tweetType":1,"viewCount":2199,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":356277157,"gmtCreate":1616784233179,"gmtModify":1634524003312,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573195863338760","idStr":"3573195863338760"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Buying more...","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Buying more...","text":"$AMC Entertainment(AMC)$Buying more...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/356277157","isVote":1,"tweetType":1,"viewCount":2191,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":351271089,"gmtCreate":1616600151741,"gmtModify":1631886377728,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573195863338760","idStr":"3573195863338760"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/BFT\">$Foley Trasimene Acquisition II Corp(BFT)$</a>🚀🚀🚀","listText":"<a href=\"https://laohu8.com/S/BFT\">$Foley Trasimene Acquisition II Corp(BFT)$</a>🚀🚀🚀","text":"$Foley Trasimene Acquisition II Corp(BFT)$🚀🚀🚀","images":[{"img":"https://static.tigerbbs.com/b1f4978bfe4b97ac969c83ac5984fa83","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/351271089","isVote":1,"tweetType":1,"viewCount":1991,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":351270319,"gmtCreate":1616600006231,"gmtModify":1634524970634,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573195863338760","idStr":"3573195863338760"},"themes":[],"title":"","htmlText":"I am going to buy more!","listText":"I am going to buy more!","text":"I am going to buy more!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/351270319","repostId":"2121457670","repostType":4,"isVote":1,"tweetType":1,"viewCount":693,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":350309242,"gmtCreate":1616156810086,"gmtModify":1631888481495,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573195863338760","idStr":"3573195863338760"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/PLUG\">$Plug Power(PLUG)$</a>next week fly?","listText":"<a href=\"https://laohu8.com/S/PLUG\">$Plug Power(PLUG)$</a>next week fly?","text":"$Plug Power(PLUG)$next week fly?","images":[{"img":"https://static.tigerbbs.com/8ead725e1e328b89ef5a9c2921ce20e6","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/350309242","isVote":1,"tweetType":1,"viewCount":1206,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":327880874,"gmtCreate":1616076200298,"gmtModify":1634527360283,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573195863338760","idStr":"3573195863338760"},"themes":[],"title":"","htmlText":"do opposite of motley fool = profit","listText":"do opposite of motley fool = profit","text":"do opposite of motley fool = profit","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/327880874","repostId":"1142227040","repostType":2,"repost":{"id":"1142227040","kind":"news","pubTimestamp":1616070253,"share":"https://www.laohu8.com/m/news/1142227040?lang=zh_CN&edition=full","pubTime":"2021-03-18 20:24","market":"us","language":"en","title":"3 Biotech Stocks to Avoid Right Now<blockquote>现在要避免的 3 只生物技术股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1142227040","media":"Motley Fool","summary":"Here's why these attention-grabbing stocks could be toxic to your portfolio.\n\nDid you know that newb","content":"<p>  <b>Here's why these attention-grabbing stocks could be toxic to your portfolio.</b>  Did you know that newbiotech stocksgo public at a rate of about one per week? With so many investment options in this space to choose from, it's a little surprising that some of the most popular companies right now haven't had much success when it comes to drug development.</p><p><blockquote><b>这就是为什么这些引人注目的股票可能对您的投资组合有害。</b>您知道新生物技术股票以每周一只左右的速度上市吗？在这个领域有如此多的投资选择可供选择，有点令人惊讶的是，目前一些最受欢迎的公司在药物开发方面没有取得太大的成功。</blockquote></p><p> Every business has a story to tell, and plenty of investors like what they've been hearing from these three. Before following the crowd, though, you should know that there are potholes along these companies' paths to success.</p><p><blockquote>每个企业都有一个故事要讲，很多投资者都喜欢他们从这三个企业那里听到的故事。不过，在随波逐流之前，你应该知道这些公司的成功之路上存在着坑洼。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/98c795e31990a6c24ab59592b22abd7a\" tg-width=\"796\" tg-height=\"207\"><b>1. Cassava Sciences</b></p><p><blockquote><b>1.木薯科学</b></blockquote></p><p> This company's developing a potential new Alzheimer's disease drug called simufilam. In the U.S., 1 in 9 people over the age of 65 have Alzheimer's disease, but there still aren't any available treatments for this progressive and ultimately fatal disease. As the first, simufilam could become one of the top-selling drugs of its time.</p><p><blockquote>这家公司正在开发一种名为simufilam的潜在新型阿尔茨海默病药物。在美国，65岁以上的人中有九分之一患有阿尔茨海默病，但这种进行性并最终致命的疾病仍然没有任何可用的治疗方法。作为第一种，simufilam 可能成为当时最畅销的药物之一。</blockquote></p><p> Following a successful phase 2 trial, Cassava Sciences told investors the Food and Drug Administration (FDA) gave the green light for a pair of phase 3 trials slated to begin in the second half of the year. If simufilam succeeds at both, shares of this biotech could explode higher.</p><p><blockquote>在成功进行 2 期试验后，Cassava Sciences 告诉投资者，美国食品药品监督管理局 (FDA) 已为定于今年下半年开始的两项 3 期试验开了绿灯。如果 simufilam 在这两点上都取得成功，这家生物技术公司的股价可能会飙升。</blockquote></p><p> Unfortunately, Cassava Sciences has been developing simufilam for over a decade and it still doesn't have any evidence from a randomized controlled trial that simufilam works as intended.</p><p><blockquote>不幸的是，木薯科学公司已经开发simufilam十多年了，但它仍然没有任何来自随机对照试验的证据表明simufilam按预期工作。</blockquote></p><p> The company included a placebo group in a smallphase 2study that read out last year, but simufilam failed to reduce signs of inflammation that show up in fluid that bathes the brain. Investigators also gave Alzheimer's disease patients cognitive tests to see if simufilam actually made a difference, but they couldn't measure an improvement.</p><p><blockquote>该公司在去年进行的一项小型 2 期研究中纳入了安慰剂组，但 simufilam 未能减少大脑液体中出现的炎症迹象。研究人员还对阿尔茨海默病患者进行了认知测试，看看simufilam是否真的产生了影响，但他们无法衡量改善。</blockquote></p><p> <b>2. Ocugen</b></p><p><blockquote><b>2. 奥库根</b></blockquote></p><p> Shares of this clinical-stage drugmaker have been soaring in response to good news for a COVID-19 vaccine called Covaxin. The vaccine's developer, Bharat Biotech, is a well-established vaccine manufacturer headquartered in India.</p><p><blockquote>这家临床阶段制药商的股价一直在飙升，以应对名为科瓦克辛的 COVID-19 疫苗的好消息。该疫苗的开发商Bharat Biotech是一家总部位于印度的知名疫苗制造商。</blockquote></p><p> Bharat Biotech has hired Ocugen to co-develop Covaxin for the U.S. market, and it looks like a winner. In a phase 3 study with over 25,000 volunteers, Covaxin was about 81% effective at preventing COVID-19 infections in India.</p><p><blockquote>Bharat Biotech 已聘请 Ocugen 为美国市场共同开发科瓦克辛，看起来是赢家。在一项涉及25,000多名志愿者的3期研究中，科瓦克辛在印度预防新冠肺炎感染方面的有效性约为81%。</blockquote></p><p> Before buying any Ocugen shares, you should know that the FDA wasn't willing to consider emergency use authorization requests without data from lots of U.S. trial volunteers when there were zero COVID-19vaccines available. Now that the agency has already authorized three safe and effective options, there's zero chance that Ocugen will sell Covaxin in the U.S. without a new phase 3 trial.</p><p><blockquote>在购买任何 Ocugen 股票之前，您应该知道，在没有 COVID-19 疫苗可用的情况下，如果没有大量美国试验志愿者的数据，FDA 不愿意考虑紧急使用授权请求。既然该机构已经授权了三种安全有效的选择，那么如果没有新的第三阶段试验，Ocugen 就不可能在美国销售科瓦克辛。</blockquote></p><p> <b>3. Rubius Therapeutics</b></p><p><blockquote><b>3. 卢比乌斯治疗公司</b></blockquote></p><p> This clinical-stage biotech is developing new cancer therapies made from a line of red blood cells that can be taken off a shelf and administered as soon as they're prescribed. Shares of Rubius have soared this year, thanks to some tumor shrinkage observed in an early-stage study with a variety of cancer patients taking its lead candidate RTX-240.</p><p><blockquote>这家临床阶段的生物技术公司正在开发由一系列红细胞制成的新型癌症疗法，这些疗法可以从货架上取下并在开出处方后立即使用。Rubius 的股价今年飙升，这要归功于在一项早期研究中观察到的一些肿瘤缩小，该研究涉及各种癌症患者服用其主要候选药物 RTX-240。</blockquote></p><p> In an interim assessment of an ascending-dosage trial that had data from 16 volunteers available, two of the patients have responded well to RTX-240 treatment. While this looks like a pretty good result for an interim analysis of an early trial, it's probably too early for anyone at Rubius to begin celebrating. That's because the only confirmed tumor shrinkage presented so far occurred for a patient treated with the lowest dosage tested.</p><p><blockquote>在一项有16名志愿者数据的递增剂量试验的中期评估中，其中两名患者对RTX-240治疗反应良好。虽然对于早期试验的中期分析来说，这看起来是一个相当不错的结果，但对于 Rubius 的任何人来说，现在开始庆祝可能还为时过早。这是因为迄今为止唯一确认的肿瘤缩小发生在接受测试的最低剂量治疗的患者身上。</blockquote></p><p> Rubius Therapeutics' red blood cells are engineered to excite and enlist different types of white blood cells to take action against tumors. The company was able to show expansion of natural killer cells and T-cells for eight patients earlier this year. Unfortunately, the company hasn't been able to show RTX-240 expanded these tumor-fighting cells for the patients who responded.</p><p><blockquote>Rubius Therapeutics 的红细胞经过改造，可以激发和招募不同类型的白细胞来对抗肿瘤。今年早些时候，该公司能够为八名患者展示自然杀伤细胞和 T 细胞的扩增。不幸的是，该公司尚未能够向有反应的患者展示 RTX-240 扩增了这些抗肿瘤细胞。</blockquote></p><p> <b>Looking forward</b></p><p><blockquote><b>向前看</b></blockquote></p><p> All of these companies have huge market valuations right now that could come crashing down if their lead programs can't deliver. That's because there's nearly nothing for them to fall back on.</p><p><blockquote>所有这些公司目前都有巨大的市场估值，如果他们的领先计划无法实现，这些估值可能会崩溃。那是因为他们几乎没有什么可以依靠的。</blockquote></p><p> Ocugen doesn't have any potential new drugs in clinical trials right now, and it's going to be a long time before we know if the gene therapies it intends to develop have a shot at success. Cassava Sciences has a potential new test for biomarkers that could indicate Alzheimer's disease, but simufilam is the only clinical-stage new drug candidate in its pipeline.</p><p><blockquote>Ocugen目前没有任何潜在的新药正在进行临床试验，我们还需要很长时间才能知道它打算开发的基因疗法是否有机会成功。Cassava Sciences 拥有一种潜在的新生物标志物测试，可以指示阿尔茨海默病，但 simufilam 是其管道中唯一处于临床阶段的新药候选药物。</blockquote></p><p> Rubius Therapeutics is developing a platform of red-blood-cell-based treatments, and the company already has a second candidate cleared by the FDA to begin clinical trials. If any of these companies has a fallback if its lead candidate doesn't work out, it's Rubius. That said, it's still way too risky to consider putting in your portfolio at the moment.</p><p><blockquote>Rubius Therapeutics正在开发一个基于红细胞的治疗平台，该公司已经有第二个候选药物获得了FDA的批准，可以开始临床试验。如果这些公司中有任何一家在其主要候选人不成功的情况下有后路的话，那就是 Rubius。也就是说，目前考虑将其纳入您的投资组合仍然风险太大。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Biotech Stocks to Avoid Right Now<blockquote>现在要避免的 3 只生物技术股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Biotech Stocks to Avoid Right Now<blockquote>现在要避免的 3 只生物技术股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-03-18 20:24</span>\n</p>\n</h4>\n</header>\n<article>\n<p>  <b>Here's why these attention-grabbing stocks could be toxic to your portfolio.</b>  Did you know that newbiotech stocksgo public at a rate of about one per week? With so many investment options in this space to choose from, it's a little surprising that some of the most popular companies right now haven't had much success when it comes to drug development.</p><p><blockquote><b>这就是为什么这些引人注目的股票可能对您的投资组合有害。</b>您知道新生物技术股票以每周一只左右的速度上市吗？在这个领域有如此多的投资选择可供选择，有点令人惊讶的是，目前一些最受欢迎的公司在药物开发方面没有取得太大的成功。</blockquote></p><p> Every business has a story to tell, and plenty of investors like what they've been hearing from these three. Before following the crowd, though, you should know that there are potholes along these companies' paths to success.</p><p><blockquote>每个企业都有一个故事要讲，很多投资者都喜欢他们从这三个企业那里听到的故事。不过，在随波逐流之前，你应该知道这些公司的成功之路上存在着坑洼。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/98c795e31990a6c24ab59592b22abd7a\" tg-width=\"796\" tg-height=\"207\"><b>1. Cassava Sciences</b></p><p><blockquote><b>1.木薯科学</b></blockquote></p><p> This company's developing a potential new Alzheimer's disease drug called simufilam. In the U.S., 1 in 9 people over the age of 65 have Alzheimer's disease, but there still aren't any available treatments for this progressive and ultimately fatal disease. As the first, simufilam could become one of the top-selling drugs of its time.</p><p><blockquote>这家公司正在开发一种名为simufilam的潜在新型阿尔茨海默病药物。在美国，65岁以上的人中有九分之一患有阿尔茨海默病，但这种进行性并最终致命的疾病仍然没有任何可用的治疗方法。作为第一种，simufilam 可能成为当时最畅销的药物之一。</blockquote></p><p> Following a successful phase 2 trial, Cassava Sciences told investors the Food and Drug Administration (FDA) gave the green light for a pair of phase 3 trials slated to begin in the second half of the year. If simufilam succeeds at both, shares of this biotech could explode higher.</p><p><blockquote>在成功进行 2 期试验后，Cassava Sciences 告诉投资者，美国食品药品监督管理局 (FDA) 已为定于今年下半年开始的两项 3 期试验开了绿灯。如果 simufilam 在这两点上都取得成功，这家生物技术公司的股价可能会飙升。</blockquote></p><p> Unfortunately, Cassava Sciences has been developing simufilam for over a decade and it still doesn't have any evidence from a randomized controlled trial that simufilam works as intended.</p><p><blockquote>不幸的是，木薯科学公司已经开发simufilam十多年了，但它仍然没有任何来自随机对照试验的证据表明simufilam按预期工作。</blockquote></p><p> The company included a placebo group in a smallphase 2study that read out last year, but simufilam failed to reduce signs of inflammation that show up in fluid that bathes the brain. Investigators also gave Alzheimer's disease patients cognitive tests to see if simufilam actually made a difference, but they couldn't measure an improvement.</p><p><blockquote>该公司在去年进行的一项小型 2 期研究中纳入了安慰剂组，但 simufilam 未能减少大脑液体中出现的炎症迹象。研究人员还对阿尔茨海默病患者进行了认知测试，看看simufilam是否真的产生了影响，但他们无法衡量改善。</blockquote></p><p> <b>2. Ocugen</b></p><p><blockquote><b>2. 奥库根</b></blockquote></p><p> Shares of this clinical-stage drugmaker have been soaring in response to good news for a COVID-19 vaccine called Covaxin. The vaccine's developer, Bharat Biotech, is a well-established vaccine manufacturer headquartered in India.</p><p><blockquote>这家临床阶段制药商的股价一直在飙升，以应对名为科瓦克辛的 COVID-19 疫苗的好消息。该疫苗的开发商Bharat Biotech是一家总部位于印度的知名疫苗制造商。</blockquote></p><p> Bharat Biotech has hired Ocugen to co-develop Covaxin for the U.S. market, and it looks like a winner. In a phase 3 study with over 25,000 volunteers, Covaxin was about 81% effective at preventing COVID-19 infections in India.</p><p><blockquote>Bharat Biotech 已聘请 Ocugen 为美国市场共同开发科瓦克辛，看起来是赢家。在一项涉及25,000多名志愿者的3期研究中，科瓦克辛在印度预防新冠肺炎感染方面的有效性约为81%。</blockquote></p><p> Before buying any Ocugen shares, you should know that the FDA wasn't willing to consider emergency use authorization requests without data from lots of U.S. trial volunteers when there were zero COVID-19vaccines available. Now that the agency has already authorized three safe and effective options, there's zero chance that Ocugen will sell Covaxin in the U.S. without a new phase 3 trial.</p><p><blockquote>在购买任何 Ocugen 股票之前，您应该知道，在没有 COVID-19 疫苗可用的情况下，如果没有大量美国试验志愿者的数据，FDA 不愿意考虑紧急使用授权请求。既然该机构已经授权了三种安全有效的选择，那么如果没有新的第三阶段试验，Ocugen 就不可能在美国销售科瓦克辛。</blockquote></p><p> <b>3. Rubius Therapeutics</b></p><p><blockquote><b>3. 卢比乌斯治疗公司</b></blockquote></p><p> This clinical-stage biotech is developing new cancer therapies made from a line of red blood cells that can be taken off a shelf and administered as soon as they're prescribed. Shares of Rubius have soared this year, thanks to some tumor shrinkage observed in an early-stage study with a variety of cancer patients taking its lead candidate RTX-240.</p><p><blockquote>这家临床阶段的生物技术公司正在开发由一系列红细胞制成的新型癌症疗法，这些疗法可以从货架上取下并在开出处方后立即使用。Rubius 的股价今年飙升，这要归功于在一项早期研究中观察到的一些肿瘤缩小，该研究涉及各种癌症患者服用其主要候选药物 RTX-240。</blockquote></p><p> In an interim assessment of an ascending-dosage trial that had data from 16 volunteers available, two of the patients have responded well to RTX-240 treatment. While this looks like a pretty good result for an interim analysis of an early trial, it's probably too early for anyone at Rubius to begin celebrating. That's because the only confirmed tumor shrinkage presented so far occurred for a patient treated with the lowest dosage tested.</p><p><blockquote>在一项有16名志愿者数据的递增剂量试验的中期评估中，其中两名患者对RTX-240治疗反应良好。虽然对于早期试验的中期分析来说，这看起来是一个相当不错的结果，但对于 Rubius 的任何人来说，现在开始庆祝可能还为时过早。这是因为迄今为止唯一确认的肿瘤缩小发生在接受测试的最低剂量治疗的患者身上。</blockquote></p><p> Rubius Therapeutics' red blood cells are engineered to excite and enlist different types of white blood cells to take action against tumors. The company was able to show expansion of natural killer cells and T-cells for eight patients earlier this year. Unfortunately, the company hasn't been able to show RTX-240 expanded these tumor-fighting cells for the patients who responded.</p><p><blockquote>Rubius Therapeutics 的红细胞经过改造，可以激发和招募不同类型的白细胞来对抗肿瘤。今年早些时候，该公司能够为八名患者展示自然杀伤细胞和 T 细胞的扩增。不幸的是，该公司尚未能够向有反应的患者展示 RTX-240 扩增了这些抗肿瘤细胞。</blockquote></p><p> <b>Looking forward</b></p><p><blockquote><b>向前看</b></blockquote></p><p> All of these companies have huge market valuations right now that could come crashing down if their lead programs can't deliver. That's because there's nearly nothing for them to fall back on.</p><p><blockquote>所有这些公司目前都有巨大的市场估值，如果他们的领先计划无法实现，这些估值可能会崩溃。那是因为他们几乎没有什么可以依靠的。</blockquote></p><p> Ocugen doesn't have any potential new drugs in clinical trials right now, and it's going to be a long time before we know if the gene therapies it intends to develop have a shot at success. Cassava Sciences has a potential new test for biomarkers that could indicate Alzheimer's disease, but simufilam is the only clinical-stage new drug candidate in its pipeline.</p><p><blockquote>Ocugen目前没有任何潜在的新药正在进行临床试验，我们还需要很长时间才能知道它打算开发的基因疗法是否有机会成功。Cassava Sciences 拥有一种潜在的新生物标志物测试，可以指示阿尔茨海默病，但 simufilam 是其管道中唯一处于临床阶段的新药候选药物。</blockquote></p><p> Rubius Therapeutics is developing a platform of red-blood-cell-based treatments, and the company already has a second candidate cleared by the FDA to begin clinical trials. If any of these companies has a fallback if its lead candidate doesn't work out, it's Rubius. That said, it's still way too risky to consider putting in your portfolio at the moment.</p><p><blockquote>Rubius Therapeutics正在开发一个基于红细胞的治疗平台，该公司已经有第二个候选药物获得了FDA的批准，可以开始临床试验。如果这些公司中有任何一家在其主要候选人不成功的情况下有后路的话，那就是 Rubius。也就是说，目前考虑将其纳入您的投资组合仍然风险太大。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/03/18/3-biotech-stocks-to-avoid-right-now/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","RUBY":"Rubius Therapeutics, Inc."},"source_url":"https://www.fool.com/investing/2021/03/18/3-biotech-stocks-to-avoid-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142227040","content_text":"Here's why these attention-grabbing stocks could be toxic to your portfolio.\n\nDid you know that newbiotech stocksgo public at a rate of about one per week? With so many investment options in this space to choose from, it's a little surprising that some of the most popular companies right now haven't had much success when it comes to drug development.\nEvery business has a story to tell, and plenty of investors like what they've been hearing from these three. Before following the crowd, though, you should know that there are potholes along these companies' paths to success.\n1. Cassava Sciences\nThis company's developing a potential new Alzheimer's disease drug called simufilam. In the U.S., 1 in 9 people over the age of 65 have Alzheimer's disease, but there still aren't any available treatments for this progressive and ultimately fatal disease. As the first, simufilam could become one of the top-selling drugs of its time.\nFollowing a successful phase 2 trial, Cassava Sciences told investors the Food and Drug Administration (FDA) gave the green light for a pair of phase 3 trials slated to begin in the second half of the year. If simufilam succeeds at both, shares of this biotech could explode higher.\nUnfortunately, Cassava Sciences has been developing simufilam for over a decade and it still doesn't have any evidence from a randomized controlled trial that simufilam works as intended.\nThe company included a placebo group in a smallphase 2study that read out last year, but simufilam failed to reduce signs of inflammation that show up in fluid that bathes the brain. Investigators also gave Alzheimer's disease patients cognitive tests to see if simufilam actually made a difference, but they couldn't measure an improvement.\n2. Ocugen\nShares of this clinical-stage drugmaker have been soaring in response to good news for a COVID-19 vaccine called Covaxin. The vaccine's developer, Bharat Biotech, is a well-established vaccine manufacturer headquartered in India.\nBharat Biotech has hired Ocugen to co-develop Covaxin for the U.S. market, and it looks like a winner. In a phase 3 study with over 25,000 volunteers, Covaxin was about 81% effective at preventing COVID-19 infections in India.\nBefore buying any Ocugen shares, you should know that the FDA wasn't willing to consider emergency use authorization requests without data from lots of U.S. trial volunteers when there were zero COVID-19vaccines available. Now that the agency has already authorized three safe and effective options, there's zero chance that Ocugen will sell Covaxin in the U.S. without a new phase 3 trial.\n3. Rubius Therapeutics\nThis clinical-stage biotech is developing new cancer therapies made from a line of red blood cells that can be taken off a shelf and administered as soon as they're prescribed. Shares of Rubius have soared this year, thanks to some tumor shrinkage observed in an early-stage study with a variety of cancer patients taking its lead candidate RTX-240.\nIn an interim assessment of an ascending-dosage trial that had data from 16 volunteers available, two of the patients have responded well to RTX-240 treatment. While this looks like a pretty good result for an interim analysis of an early trial, it's probably too early for anyone at Rubius to begin celebrating. That's because the only confirmed tumor shrinkage presented so far occurred for a patient treated with the lowest dosage tested.\nRubius Therapeutics' red blood cells are engineered to excite and enlist different types of white blood cells to take action against tumors. The company was able to show expansion of natural killer cells and T-cells for eight patients earlier this year. Unfortunately, the company hasn't been able to show RTX-240 expanded these tumor-fighting cells for the patients who responded.\nLooking forward\nAll of these companies have huge market valuations right now that could come crashing down if their lead programs can't deliver. That's because there's nearly nothing for them to fall back on.\nOcugen doesn't have any potential new drugs in clinical trials right now, and it's going to be a long time before we know if the gene therapies it intends to develop have a shot at success. Cassava Sciences has a potential new test for biomarkers that could indicate Alzheimer's disease, but simufilam is the only clinical-stage new drug candidate in its pipeline.\nRubius Therapeutics is developing a platform of red-blood-cell-based treatments, and the company already has a second candidate cleared by the FDA to begin clinical trials. If any of these companies has a fallback if its lead candidate doesn't work out, it's Rubius. That said, it's still way too risky to consider putting in your portfolio at the moment.","news_type":1,"symbols_score_info":{"RUBY":0.9,"OCGN":0.9,"SAVA":0.9}},"isVote":1,"tweetType":1,"viewCount":611,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":325425124,"gmtCreate":1615918519668,"gmtModify":1703495065912,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573195863338760","idStr":"3573195863338760"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>🚀🚀🚀","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>🚀🚀🚀","text":"$AMC Entertainment(AMC)$🚀🚀🚀","images":[{"img":"https://static.tigerbbs.com/7024feb9c880935d6c97f44c027d07cf","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":1,"link":"https://laohu8.com/post/325425124","isVote":1,"tweetType":1,"viewCount":576,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":325498248,"gmtCreate":1615910442384,"gmtModify":1703494988439,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573195863338760","idStr":"3573195863338760"},"themes":[],"title":"","htmlText":"price target $200","listText":"price target $200","text":"price target $200","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/325498248","repostId":"2119976011","repostType":2,"isVote":1,"tweetType":1,"viewCount":570,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":322725231,"gmtCreate":1615833623223,"gmtModify":1703493787967,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573195863338760","idStr":"3573195863338760"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/SURF\">$Surface Oncology(SURF)$</a>Hold...","listText":"<a href=\"https://laohu8.com/S/SURF\">$Surface Oncology(SURF)$</a>Hold...","text":"$Surface Oncology(SURF)$Hold...","images":[{"img":"https://static.tigerbbs.com/50d6181fd77e12a4a22371ecc9d3df45","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/322725231","isVote":1,"tweetType":1,"viewCount":551,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":328777306,"gmtCreate":1615562261805,"gmtModify":1703491016980,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573195863338760","idStr":"3573195863338760"},"themes":[],"title":"","htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a> paper hand last time but not this time","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a> paper hand last time but not this time","text":"$AMC Entertainment(AMC)$ paper hand last time but not this time","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/328777306","isVote":1,"tweetType":1,"viewCount":780,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":328954586,"gmtCreate":1615481925545,"gmtModify":1703489843859,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573195863338760","idStr":"3573195863338760"},"themes":[],"title":"","htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a> let's go! back to $18","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a> let's go! back to $18","text":"$Histogenics(OCGN)$ let's go! back to $18","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/328954586","isVote":1,"tweetType":1,"viewCount":631,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":388637387,"gmtCreate":1613053634749,"gmtModify":1703768858439,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573195863338760","idStr":"3573195863338760"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>Happy Chinese New Year 💎🖐","listText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>Happy Chinese New Year 💎🖐","text":"$Histogenics(OCGN)$Happy Chinese New Year 💎🖐","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/388637387","isVote":1,"tweetType":1,"viewCount":540,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":383708394,"gmtCreate":1612889562018,"gmtModify":1703766617420,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573195863338760","idStr":"3573195863338760"},"themes":[],"title":"","htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a> lets go $20","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a> lets go $20","text":"$Histogenics(OCGN)$ lets go $20","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/383708394","isVote":1,"tweetType":1,"viewCount":879,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":325425124,"gmtCreate":1615918519668,"gmtModify":1703495065912,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573195863338760","idStr":"3573195863338760"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>🚀🚀🚀","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>🚀🚀🚀","text":"$AMC Entertainment(AMC)$🚀🚀🚀","images":[{"img":"https://static.tigerbbs.com/7024feb9c880935d6c97f44c027d07cf","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":1,"link":"https://laohu8.com/post/325425124","isVote":1,"tweetType":1,"viewCount":576,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":100499694,"gmtCreate":1619626119018,"gmtModify":1634211211506,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573195863338760","idStr":"3573195863338760"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Drop to $9 time to&nbsp;double down...","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Drop to $9 time to&nbsp;double down...","text":"$AMC Entertainment(AMC)$Drop to $9 time to double down...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/100499694","isVote":1,"tweetType":1,"viewCount":3088,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":356277157,"gmtCreate":1616784233179,"gmtModify":1634524003312,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573195863338760","idStr":"3573195863338760"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Buying more...","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Buying more...","text":"$AMC Entertainment(AMC)$Buying more...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/356277157","isVote":1,"tweetType":1,"viewCount":2191,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":351270319,"gmtCreate":1616600006231,"gmtModify":1634524970634,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573195863338760","idStr":"3573195863338760"},"themes":[],"title":"","htmlText":"I am going to buy more!","listText":"I am going to buy more!","text":"I am going to buy more!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/351270319","repostId":"2121457670","repostType":4,"isVote":1,"tweetType":1,"viewCount":693,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":328954586,"gmtCreate":1615481925545,"gmtModify":1703489843859,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573195863338760","idStr":"3573195863338760"},"themes":[],"title":"","htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a> let's go! back to $18","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a> let's go! back to $18","text":"$Histogenics(OCGN)$ let's go! back to $18","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/328954586","isVote":1,"tweetType":1,"viewCount":631,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":357769122,"gmtCreate":1617302142866,"gmtModify":1631886377613,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573195863338760","idStr":"3573195863338760"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/PSFE\">$Paysafe Ltd(PSFE)$</a>Rise","listText":"<a href=\"https://laohu8.com/S/PSFE\">$Paysafe Ltd(PSFE)$</a>Rise","text":"$Paysafe Ltd(PSFE)$Rise","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/357769122","isVote":1,"tweetType":1,"viewCount":2080,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":327880874,"gmtCreate":1616076200298,"gmtModify":1634527360283,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573195863338760","idStr":"3573195863338760"},"themes":[],"title":"","htmlText":"do opposite of motley fool = profit","listText":"do opposite of motley fool = profit","text":"do opposite of motley fool = profit","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/327880874","repostId":"1142227040","repostType":2,"repost":{"id":"1142227040","kind":"news","pubTimestamp":1616070253,"share":"https://www.laohu8.com/m/news/1142227040?lang=zh_CN&edition=full","pubTime":"2021-03-18 20:24","market":"us","language":"en","title":"3 Biotech Stocks to Avoid Right Now<blockquote>现在要避免的 3 只生物技术股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1142227040","media":"Motley Fool","summary":"Here's why these attention-grabbing stocks could be toxic to your portfolio.\n\nDid you know that newb","content":"<p>  <b>Here's why these attention-grabbing stocks could be toxic to your portfolio.</b>  Did you know that newbiotech stocksgo public at a rate of about one per week? With so many investment options in this space to choose from, it's a little surprising that some of the most popular companies right now haven't had much success when it comes to drug development.</p><p><blockquote><b>这就是为什么这些引人注目的股票可能对您的投资组合有害。</b>您知道新生物技术股票以每周一只左右的速度上市吗？在这个领域有如此多的投资选择可供选择，有点令人惊讶的是，目前一些最受欢迎的公司在药物开发方面没有取得太大的成功。</blockquote></p><p> Every business has a story to tell, and plenty of investors like what they've been hearing from these three. Before following the crowd, though, you should know that there are potholes along these companies' paths to success.</p><p><blockquote>每个企业都有一个故事要讲，很多投资者都喜欢他们从这三个企业那里听到的故事。不过，在随波逐流之前，你应该知道这些公司的成功之路上存在着坑洼。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/98c795e31990a6c24ab59592b22abd7a\" tg-width=\"796\" tg-height=\"207\"><b>1. Cassava Sciences</b></p><p><blockquote><b>1.木薯科学</b></blockquote></p><p> This company's developing a potential new Alzheimer's disease drug called simufilam. In the U.S., 1 in 9 people over the age of 65 have Alzheimer's disease, but there still aren't any available treatments for this progressive and ultimately fatal disease. As the first, simufilam could become one of the top-selling drugs of its time.</p><p><blockquote>这家公司正在开发一种名为simufilam的潜在新型阿尔茨海默病药物。在美国，65岁以上的人中有九分之一患有阿尔茨海默病，但这种进行性并最终致命的疾病仍然没有任何可用的治疗方法。作为第一种，simufilam 可能成为当时最畅销的药物之一。</blockquote></p><p> Following a successful phase 2 trial, Cassava Sciences told investors the Food and Drug Administration (FDA) gave the green light for a pair of phase 3 trials slated to begin in the second half of the year. If simufilam succeeds at both, shares of this biotech could explode higher.</p><p><blockquote>在成功进行 2 期试验后，Cassava Sciences 告诉投资者，美国食品药品监督管理局 (FDA) 已为定于今年下半年开始的两项 3 期试验开了绿灯。如果 simufilam 在这两点上都取得成功，这家生物技术公司的股价可能会飙升。</blockquote></p><p> Unfortunately, Cassava Sciences has been developing simufilam for over a decade and it still doesn't have any evidence from a randomized controlled trial that simufilam works as intended.</p><p><blockquote>不幸的是，木薯科学公司已经开发simufilam十多年了，但它仍然没有任何来自随机对照试验的证据表明simufilam按预期工作。</blockquote></p><p> The company included a placebo group in a smallphase 2study that read out last year, but simufilam failed to reduce signs of inflammation that show up in fluid that bathes the brain. Investigators also gave Alzheimer's disease patients cognitive tests to see if simufilam actually made a difference, but they couldn't measure an improvement.</p><p><blockquote>该公司在去年进行的一项小型 2 期研究中纳入了安慰剂组，但 simufilam 未能减少大脑液体中出现的炎症迹象。研究人员还对阿尔茨海默病患者进行了认知测试，看看simufilam是否真的产生了影响，但他们无法衡量改善。</blockquote></p><p> <b>2. Ocugen</b></p><p><blockquote><b>2. 奥库根</b></blockquote></p><p> Shares of this clinical-stage drugmaker have been soaring in response to good news for a COVID-19 vaccine called Covaxin. The vaccine's developer, Bharat Biotech, is a well-established vaccine manufacturer headquartered in India.</p><p><blockquote>这家临床阶段制药商的股价一直在飙升，以应对名为科瓦克辛的 COVID-19 疫苗的好消息。该疫苗的开发商Bharat Biotech是一家总部位于印度的知名疫苗制造商。</blockquote></p><p> Bharat Biotech has hired Ocugen to co-develop Covaxin for the U.S. market, and it looks like a winner. In a phase 3 study with over 25,000 volunteers, Covaxin was about 81% effective at preventing COVID-19 infections in India.</p><p><blockquote>Bharat Biotech 已聘请 Ocugen 为美国市场共同开发科瓦克辛，看起来是赢家。在一项涉及25,000多名志愿者的3期研究中，科瓦克辛在印度预防新冠肺炎感染方面的有效性约为81%。</blockquote></p><p> Before buying any Ocugen shares, you should know that the FDA wasn't willing to consider emergency use authorization requests without data from lots of U.S. trial volunteers when there were zero COVID-19vaccines available. Now that the agency has already authorized three safe and effective options, there's zero chance that Ocugen will sell Covaxin in the U.S. without a new phase 3 trial.</p><p><blockquote>在购买任何 Ocugen 股票之前，您应该知道，在没有 COVID-19 疫苗可用的情况下，如果没有大量美国试验志愿者的数据，FDA 不愿意考虑紧急使用授权请求。既然该机构已经授权了三种安全有效的选择，那么如果没有新的第三阶段试验，Ocugen 就不可能在美国销售科瓦克辛。</blockquote></p><p> <b>3. Rubius Therapeutics</b></p><p><blockquote><b>3. 卢比乌斯治疗公司</b></blockquote></p><p> This clinical-stage biotech is developing new cancer therapies made from a line of red blood cells that can be taken off a shelf and administered as soon as they're prescribed. Shares of Rubius have soared this year, thanks to some tumor shrinkage observed in an early-stage study with a variety of cancer patients taking its lead candidate RTX-240.</p><p><blockquote>这家临床阶段的生物技术公司正在开发由一系列红细胞制成的新型癌症疗法，这些疗法可以从货架上取下并在开出处方后立即使用。Rubius 的股价今年飙升，这要归功于在一项早期研究中观察到的一些肿瘤缩小，该研究涉及各种癌症患者服用其主要候选药物 RTX-240。</blockquote></p><p> In an interim assessment of an ascending-dosage trial that had data from 16 volunteers available, two of the patients have responded well to RTX-240 treatment. While this looks like a pretty good result for an interim analysis of an early trial, it's probably too early for anyone at Rubius to begin celebrating. That's because the only confirmed tumor shrinkage presented so far occurred for a patient treated with the lowest dosage tested.</p><p><blockquote>在一项有16名志愿者数据的递增剂量试验的中期评估中，其中两名患者对RTX-240治疗反应良好。虽然对于早期试验的中期分析来说，这看起来是一个相当不错的结果，但对于 Rubius 的任何人来说，现在开始庆祝可能还为时过早。这是因为迄今为止唯一确认的肿瘤缩小发生在接受测试的最低剂量治疗的患者身上。</blockquote></p><p> Rubius Therapeutics' red blood cells are engineered to excite and enlist different types of white blood cells to take action against tumors. The company was able to show expansion of natural killer cells and T-cells for eight patients earlier this year. Unfortunately, the company hasn't been able to show RTX-240 expanded these tumor-fighting cells for the patients who responded.</p><p><blockquote>Rubius Therapeutics 的红细胞经过改造，可以激发和招募不同类型的白细胞来对抗肿瘤。今年早些时候，该公司能够为八名患者展示自然杀伤细胞和 T 细胞的扩增。不幸的是，该公司尚未能够向有反应的患者展示 RTX-240 扩增了这些抗肿瘤细胞。</blockquote></p><p> <b>Looking forward</b></p><p><blockquote><b>向前看</b></blockquote></p><p> All of these companies have huge market valuations right now that could come crashing down if their lead programs can't deliver. That's because there's nearly nothing for them to fall back on.</p><p><blockquote>所有这些公司目前都有巨大的市场估值，如果他们的领先计划无法实现，这些估值可能会崩溃。那是因为他们几乎没有什么可以依靠的。</blockquote></p><p> Ocugen doesn't have any potential new drugs in clinical trials right now, and it's going to be a long time before we know if the gene therapies it intends to develop have a shot at success. Cassava Sciences has a potential new test for biomarkers that could indicate Alzheimer's disease, but simufilam is the only clinical-stage new drug candidate in its pipeline.</p><p><blockquote>Ocugen目前没有任何潜在的新药正在进行临床试验，我们还需要很长时间才能知道它打算开发的基因疗法是否有机会成功。Cassava Sciences 拥有一种潜在的新生物标志物测试，可以指示阿尔茨海默病，但 simufilam 是其管道中唯一处于临床阶段的新药候选药物。</blockquote></p><p> Rubius Therapeutics is developing a platform of red-blood-cell-based treatments, and the company already has a second candidate cleared by the FDA to begin clinical trials. If any of these companies has a fallback if its lead candidate doesn't work out, it's Rubius. That said, it's still way too risky to consider putting in your portfolio at the moment.</p><p><blockquote>Rubius Therapeutics正在开发一个基于红细胞的治疗平台，该公司已经有第二个候选药物获得了FDA的批准，可以开始临床试验。如果这些公司中有任何一家在其主要候选人不成功的情况下有后路的话，那就是 Rubius。也就是说，目前考虑将其纳入您的投资组合仍然风险太大。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Biotech Stocks to Avoid Right Now<blockquote>现在要避免的 3 只生物技术股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Biotech Stocks to Avoid Right Now<blockquote>现在要避免的 3 只生物技术股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-03-18 20:24</span>\n</p>\n</h4>\n</header>\n<article>\n<p>  <b>Here's why these attention-grabbing stocks could be toxic to your portfolio.</b>  Did you know that newbiotech stocksgo public at a rate of about one per week? With so many investment options in this space to choose from, it's a little surprising that some of the most popular companies right now haven't had much success when it comes to drug development.</p><p><blockquote><b>这就是为什么这些引人注目的股票可能对您的投资组合有害。</b>您知道新生物技术股票以每周一只左右的速度上市吗？在这个领域有如此多的投资选择可供选择，有点令人惊讶的是，目前一些最受欢迎的公司在药物开发方面没有取得太大的成功。</blockquote></p><p> Every business has a story to tell, and plenty of investors like what they've been hearing from these three. Before following the crowd, though, you should know that there are potholes along these companies' paths to success.</p><p><blockquote>每个企业都有一个故事要讲，很多投资者都喜欢他们从这三个企业那里听到的故事。不过，在随波逐流之前，你应该知道这些公司的成功之路上存在着坑洼。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/98c795e31990a6c24ab59592b22abd7a\" tg-width=\"796\" tg-height=\"207\"><b>1. Cassava Sciences</b></p><p><blockquote><b>1.木薯科学</b></blockquote></p><p> This company's developing a potential new Alzheimer's disease drug called simufilam. In the U.S., 1 in 9 people over the age of 65 have Alzheimer's disease, but there still aren't any available treatments for this progressive and ultimately fatal disease. As the first, simufilam could become one of the top-selling drugs of its time.</p><p><blockquote>这家公司正在开发一种名为simufilam的潜在新型阿尔茨海默病药物。在美国，65岁以上的人中有九分之一患有阿尔茨海默病，但这种进行性并最终致命的疾病仍然没有任何可用的治疗方法。作为第一种，simufilam 可能成为当时最畅销的药物之一。</blockquote></p><p> Following a successful phase 2 trial, Cassava Sciences told investors the Food and Drug Administration (FDA) gave the green light for a pair of phase 3 trials slated to begin in the second half of the year. If simufilam succeeds at both, shares of this biotech could explode higher.</p><p><blockquote>在成功进行 2 期试验后，Cassava Sciences 告诉投资者，美国食品药品监督管理局 (FDA) 已为定于今年下半年开始的两项 3 期试验开了绿灯。如果 simufilam 在这两点上都取得成功，这家生物技术公司的股价可能会飙升。</blockquote></p><p> Unfortunately, Cassava Sciences has been developing simufilam for over a decade and it still doesn't have any evidence from a randomized controlled trial that simufilam works as intended.</p><p><blockquote>不幸的是，木薯科学公司已经开发simufilam十多年了，但它仍然没有任何来自随机对照试验的证据表明simufilam按预期工作。</blockquote></p><p> The company included a placebo group in a smallphase 2study that read out last year, but simufilam failed to reduce signs of inflammation that show up in fluid that bathes the brain. Investigators also gave Alzheimer's disease patients cognitive tests to see if simufilam actually made a difference, but they couldn't measure an improvement.</p><p><blockquote>该公司在去年进行的一项小型 2 期研究中纳入了安慰剂组，但 simufilam 未能减少大脑液体中出现的炎症迹象。研究人员还对阿尔茨海默病患者进行了认知测试，看看simufilam是否真的产生了影响，但他们无法衡量改善。</blockquote></p><p> <b>2. Ocugen</b></p><p><blockquote><b>2. 奥库根</b></blockquote></p><p> Shares of this clinical-stage drugmaker have been soaring in response to good news for a COVID-19 vaccine called Covaxin. The vaccine's developer, Bharat Biotech, is a well-established vaccine manufacturer headquartered in India.</p><p><blockquote>这家临床阶段制药商的股价一直在飙升，以应对名为科瓦克辛的 COVID-19 疫苗的好消息。该疫苗的开发商Bharat Biotech是一家总部位于印度的知名疫苗制造商。</blockquote></p><p> Bharat Biotech has hired Ocugen to co-develop Covaxin for the U.S. market, and it looks like a winner. In a phase 3 study with over 25,000 volunteers, Covaxin was about 81% effective at preventing COVID-19 infections in India.</p><p><blockquote>Bharat Biotech 已聘请 Ocugen 为美国市场共同开发科瓦克辛，看起来是赢家。在一项涉及25,000多名志愿者的3期研究中，科瓦克辛在印度预防新冠肺炎感染方面的有效性约为81%。</blockquote></p><p> Before buying any Ocugen shares, you should know that the FDA wasn't willing to consider emergency use authorization requests without data from lots of U.S. trial volunteers when there were zero COVID-19vaccines available. Now that the agency has already authorized three safe and effective options, there's zero chance that Ocugen will sell Covaxin in the U.S. without a new phase 3 trial.</p><p><blockquote>在购买任何 Ocugen 股票之前，您应该知道，在没有 COVID-19 疫苗可用的情况下，如果没有大量美国试验志愿者的数据，FDA 不愿意考虑紧急使用授权请求。既然该机构已经授权了三种安全有效的选择，那么如果没有新的第三阶段试验，Ocugen 就不可能在美国销售科瓦克辛。</blockquote></p><p> <b>3. Rubius Therapeutics</b></p><p><blockquote><b>3. 卢比乌斯治疗公司</b></blockquote></p><p> This clinical-stage biotech is developing new cancer therapies made from a line of red blood cells that can be taken off a shelf and administered as soon as they're prescribed. Shares of Rubius have soared this year, thanks to some tumor shrinkage observed in an early-stage study with a variety of cancer patients taking its lead candidate RTX-240.</p><p><blockquote>这家临床阶段的生物技术公司正在开发由一系列红细胞制成的新型癌症疗法，这些疗法可以从货架上取下并在开出处方后立即使用。Rubius 的股价今年飙升，这要归功于在一项早期研究中观察到的一些肿瘤缩小，该研究涉及各种癌症患者服用其主要候选药物 RTX-240。</blockquote></p><p> In an interim assessment of an ascending-dosage trial that had data from 16 volunteers available, two of the patients have responded well to RTX-240 treatment. While this looks like a pretty good result for an interim analysis of an early trial, it's probably too early for anyone at Rubius to begin celebrating. That's because the only confirmed tumor shrinkage presented so far occurred for a patient treated with the lowest dosage tested.</p><p><blockquote>在一项有16名志愿者数据的递增剂量试验的中期评估中，其中两名患者对RTX-240治疗反应良好。虽然对于早期试验的中期分析来说，这看起来是一个相当不错的结果，但对于 Rubius 的任何人来说，现在开始庆祝可能还为时过早。这是因为迄今为止唯一确认的肿瘤缩小发生在接受测试的最低剂量治疗的患者身上。</blockquote></p><p> Rubius Therapeutics' red blood cells are engineered to excite and enlist different types of white blood cells to take action against tumors. The company was able to show expansion of natural killer cells and T-cells for eight patients earlier this year. Unfortunately, the company hasn't been able to show RTX-240 expanded these tumor-fighting cells for the patients who responded.</p><p><blockquote>Rubius Therapeutics 的红细胞经过改造，可以激发和招募不同类型的白细胞来对抗肿瘤。今年早些时候，该公司能够为八名患者展示自然杀伤细胞和 T 细胞的扩增。不幸的是，该公司尚未能够向有反应的患者展示 RTX-240 扩增了这些抗肿瘤细胞。</blockquote></p><p> <b>Looking forward</b></p><p><blockquote><b>向前看</b></blockquote></p><p> All of these companies have huge market valuations right now that could come crashing down if their lead programs can't deliver. That's because there's nearly nothing for them to fall back on.</p><p><blockquote>所有这些公司目前都有巨大的市场估值，如果他们的领先计划无法实现，这些估值可能会崩溃。那是因为他们几乎没有什么可以依靠的。</blockquote></p><p> Ocugen doesn't have any potential new drugs in clinical trials right now, and it's going to be a long time before we know if the gene therapies it intends to develop have a shot at success. Cassava Sciences has a potential new test for biomarkers that could indicate Alzheimer's disease, but simufilam is the only clinical-stage new drug candidate in its pipeline.</p><p><blockquote>Ocugen目前没有任何潜在的新药正在进行临床试验，我们还需要很长时间才能知道它打算开发的基因疗法是否有机会成功。Cassava Sciences 拥有一种潜在的新生物标志物测试，可以指示阿尔茨海默病，但 simufilam 是其管道中唯一处于临床阶段的新药候选药物。</blockquote></p><p> Rubius Therapeutics is developing a platform of red-blood-cell-based treatments, and the company already has a second candidate cleared by the FDA to begin clinical trials. If any of these companies has a fallback if its lead candidate doesn't work out, it's Rubius. That said, it's still way too risky to consider putting in your portfolio at the moment.</p><p><blockquote>Rubius Therapeutics正在开发一个基于红细胞的治疗平台，该公司已经有第二个候选药物获得了FDA的批准，可以开始临床试验。如果这些公司中有任何一家在其主要候选人不成功的情况下有后路的话，那就是 Rubius。也就是说，目前考虑将其纳入您的投资组合仍然风险太大。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/03/18/3-biotech-stocks-to-avoid-right-now/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","RUBY":"Rubius Therapeutics, Inc."},"source_url":"https://www.fool.com/investing/2021/03/18/3-biotech-stocks-to-avoid-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142227040","content_text":"Here's why these attention-grabbing stocks could be toxic to your portfolio.\n\nDid you know that newbiotech stocksgo public at a rate of about one per week? With so many investment options in this space to choose from, it's a little surprising that some of the most popular companies right now haven't had much success when it comes to drug development.\nEvery business has a story to tell, and plenty of investors like what they've been hearing from these three. Before following the crowd, though, you should know that there are potholes along these companies' paths to success.\n1. Cassava Sciences\nThis company's developing a potential new Alzheimer's disease drug called simufilam. In the U.S., 1 in 9 people over the age of 65 have Alzheimer's disease, but there still aren't any available treatments for this progressive and ultimately fatal disease. As the first, simufilam could become one of the top-selling drugs of its time.\nFollowing a successful phase 2 trial, Cassava Sciences told investors the Food and Drug Administration (FDA) gave the green light for a pair of phase 3 trials slated to begin in the second half of the year. If simufilam succeeds at both, shares of this biotech could explode higher.\nUnfortunately, Cassava Sciences has been developing simufilam for over a decade and it still doesn't have any evidence from a randomized controlled trial that simufilam works as intended.\nThe company included a placebo group in a smallphase 2study that read out last year, but simufilam failed to reduce signs of inflammation that show up in fluid that bathes the brain. Investigators also gave Alzheimer's disease patients cognitive tests to see if simufilam actually made a difference, but they couldn't measure an improvement.\n2. Ocugen\nShares of this clinical-stage drugmaker have been soaring in response to good news for a COVID-19 vaccine called Covaxin. The vaccine's developer, Bharat Biotech, is a well-established vaccine manufacturer headquartered in India.\nBharat Biotech has hired Ocugen to co-develop Covaxin for the U.S. market, and it looks like a winner. In a phase 3 study with over 25,000 volunteers, Covaxin was about 81% effective at preventing COVID-19 infections in India.\nBefore buying any Ocugen shares, you should know that the FDA wasn't willing to consider emergency use authorization requests without data from lots of U.S. trial volunteers when there were zero COVID-19vaccines available. Now that the agency has already authorized three safe and effective options, there's zero chance that Ocugen will sell Covaxin in the U.S. without a new phase 3 trial.\n3. Rubius Therapeutics\nThis clinical-stage biotech is developing new cancer therapies made from a line of red blood cells that can be taken off a shelf and administered as soon as they're prescribed. Shares of Rubius have soared this year, thanks to some tumor shrinkage observed in an early-stage study with a variety of cancer patients taking its lead candidate RTX-240.\nIn an interim assessment of an ascending-dosage trial that had data from 16 volunteers available, two of the patients have responded well to RTX-240 treatment. While this looks like a pretty good result for an interim analysis of an early trial, it's probably too early for anyone at Rubius to begin celebrating. That's because the only confirmed tumor shrinkage presented so far occurred for a patient treated with the lowest dosage tested.\nRubius Therapeutics' red blood cells are engineered to excite and enlist different types of white blood cells to take action against tumors. The company was able to show expansion of natural killer cells and T-cells for eight patients earlier this year. Unfortunately, the company hasn't been able to show RTX-240 expanded these tumor-fighting cells for the patients who responded.\nLooking forward\nAll of these companies have huge market valuations right now that could come crashing down if their lead programs can't deliver. That's because there's nearly nothing for them to fall back on.\nOcugen doesn't have any potential new drugs in clinical trials right now, and it's going to be a long time before we know if the gene therapies it intends to develop have a shot at success. Cassava Sciences has a potential new test for biomarkers that could indicate Alzheimer's disease, but simufilam is the only clinical-stage new drug candidate in its pipeline.\nRubius Therapeutics is developing a platform of red-blood-cell-based treatments, and the company already has a second candidate cleared by the FDA to begin clinical trials. If any of these companies has a fallback if its lead candidate doesn't work out, it's Rubius. That said, it's still way too risky to consider putting in your portfolio at the moment.","news_type":1,"symbols_score_info":{"RUBY":0.9,"OCGN":0.9,"SAVA":0.9}},"isVote":1,"tweetType":1,"viewCount":611,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":355153979,"gmtCreate":1617041728691,"gmtModify":1631886377700,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573195863338760","idStr":"3573195863338760"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/BFT\">$Foley Trasimene Acquisition II Corp(BFT)$</a>[贱笑]&nbsp;","listText":"<a href=\"https://laohu8.com/S/BFT\">$Foley Trasimene Acquisition II Corp(BFT)$</a>[贱笑]&nbsp;","text":"$Foley Trasimene Acquisition II Corp(BFT)$[贱笑]","images":[{"img":"https://static.tigerbbs.com/4d103a9d850a22d203508f25c16a1c73","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/355153979","isVote":1,"tweetType":1,"viewCount":2199,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":350309242,"gmtCreate":1616156810086,"gmtModify":1631888481495,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573195863338760","idStr":"3573195863338760"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/PLUG\">$Plug Power(PLUG)$</a>next week fly?","listText":"<a href=\"https://laohu8.com/S/PLUG\">$Plug Power(PLUG)$</a>next week fly?","text":"$Plug Power(PLUG)$next week fly?","images":[{"img":"https://static.tigerbbs.com/8ead725e1e328b89ef5a9c2921ce20e6","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/350309242","isVote":1,"tweetType":1,"viewCount":1206,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":311988574,"gmtCreate":1611759544198,"gmtModify":1703753342311,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573195863338760","idStr":"3573195863338760"},"themes":[],"title":"","htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/GME\">$GameStop(GME)$</a> to the moon!","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/GME\">$GameStop(GME)$</a> to the moon!","text":"$GameStop(GME)$ to the moon!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/311988574","isVote":1,"tweetType":1,"viewCount":812,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}